Skip to main content

Advertisement

Log in

Temozolomide in malignant gliomas: current use and future targets

  • Mini Review
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

Abstract

Temozolomide (TMZ) is an oral alkylating agent that is regarded as a tolerable and effective drug. When combined with radiotherapy in patients with newly diagnosed glioblastoma, survival is significantly prolonged. This finding has led to widespread use of TMZ for patients with this disease. We summarize developing concerns regarding the use of TMZ, imaging of malignant gliomas, and the pharmacology of TMZ—mechanism of action, scheduling and strategies for overcoming resistance.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Stupp R, Mason WP, van den Bent MJ et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987–996

    Article  PubMed  CAS  Google Scholar 

  2. Stupp R, Hegi ME, Mason WP et al (2009) Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 10:459–466

    Article  PubMed  CAS  Google Scholar 

  3. CBTRUS (2008) Statistical report: primary brain tumors in the United States, 2000–2004. In: Edition Published by the Central Brain Tumor Registry of the United States 2008

  4. Stewart LA (2002) Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials. Lancet 359:1011–1018

    Article  PubMed  CAS  Google Scholar 

  5. Fine HA, Dear KB, Loeffler JS et al (1993) Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults. Cancer 71:2585–2597

    Article  PubMed  CAS  Google Scholar 

  6. Westphal M, Hilt DC, Bortey E et al (2003) A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma. Neuro Oncol 5:79–88

    Article  PubMed  CAS  Google Scholar 

  7. http://www.accessdata.fda.gov/scripts/cder/onctools/druglist.cfm. Accessed 19 May 2009

  8. Stupp R, Dietrich PY, Ostermann Kraljevic S et al (2002) Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide. J Clin Oncol 20:1375–1382

    Article  PubMed  CAS  Google Scholar 

  9. Yung WK, Albright RE, Olson J et al (2000) A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse. Br J Cancer 83:588–593

    Article  PubMed  CAS  Google Scholar 

  10. Yung WK, Prados MD, Yaya-Tur R et al (1999) Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group. J Clin Oncol 17:2762–2771

    PubMed  CAS  Google Scholar 

  11. Curran WJ Jr, Scott CB, Horton J et al (1993) Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials. J Natl Cancer Inst 85:704–710

    Article  PubMed  Google Scholar 

  12. Mirimanoff RO, Gorlia T, Mason W et al (2006) Radiotherapy and temozolomide for newly diagnosed glioblastoma: recursive partitioning analysis of the EORTC 26981/22981-NCIC CE3 phase III randomized trial. J Clin Oncol 24:2563–2569

    Article  PubMed  CAS  Google Scholar 

  13. Esteller M, Garcia-Foncillas J, Andion E et al (2000) Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med 343:1350–1354

    Article  PubMed  CAS  Google Scholar 

  14. Hegi ME, Diserens AC, Gorlia T et al (2005) MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352:997–1003

    Article  PubMed  CAS  Google Scholar 

  15. Keime-Guibert F, Chinot O, Taillandier L et al (2007) Radiotherapy for glioblastoma in the elderly. N Engl J Med 356:1527–1535

    Article  PubMed  CAS  Google Scholar 

  16. Chinot OL, Barrie M, Frauger E et al (2004) Phase II study of temozolomide without radiotherapy in newly diagnosed glioblastoma multiforme in an elderly populations. Cancer 100:2208–2214

    Article  PubMed  CAS  Google Scholar 

  17. Glantz M, Chamberlain M, Liu Q et al (2003) Temozolomide as an alternative to irradiation for elderly patients with newly diagnosed malignant gliomas. Cancer 97:2262–2266

    Article  PubMed  CAS  Google Scholar 

  18. Kimple RJ, Grabowski S, Papez M et al (2008) Glioblastoma in the elderly: radiation, chemoradiation, and supportive care. J Clin Oncol 26 (abstr 20738)

  19. Baker SD, Wirth M, Statkevich P et al (1999) Absorption, metabolism, and excretion of 14C-temozolomide following oral administration to patients with advanced cancer. Clin Cancer Res 5:309–317

    PubMed  CAS  Google Scholar 

  20. Newlands ES, Stevens MF, Wedge SR et al (1997) Temozolomide: a review of its discovery, chemical properties, pre-clinical development and clinical trials. Cancer Treat Rev 23:35–61

    Article  PubMed  CAS  Google Scholar 

  21. Muldoon LL, Soussain C, Jahnke K et al (2007) Chemotherapy delivery issues in central nervous system malignancy: a reality check. J Clin Oncol 25:2295–2305

    Article  PubMed  CAS  Google Scholar 

  22. Marchesi F, Turriziani M, Tortorelli G et al (2007) Triazene compounds: mechanism of action and related DNA repair systems. Pharmacol Res 56:275–287

    Article  PubMed  CAS  Google Scholar 

  23. Kanzawa T, Bedwell J, Kondo Y et al (2003) Inhibition of DNA repair for sensitizing resistant glioma cells to temozolomide. J Neurosurg 99:1047–1052

    Article  PubMed  CAS  Google Scholar 

  24. Roos WP, Batista LF, Naumann SC et al (2007) Apoptosis in malignant glioma cells triggered by the temozolomide-induced DNA lesion O6-methylguanine. Oncogene 26:186–197

    Article  PubMed  CAS  Google Scholar 

  25. Ziegler DS, Kung AL, Kieran MW (2008) Anti-apoptosis mechanisms in malignant gliomas. J Clin Oncol 26:493–500

    Article  PubMed  CAS  Google Scholar 

  26. Tolcher AW, Gerson SL, Denis L et al (2003) Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules. Br J Cancer 88:1004–1011

    Article  PubMed  CAS  Google Scholar 

  27. Balmaceda C, Peereboom D, Pannullo S et al (2008) Multi-institutional phase II study of temozolomide administered twice daily in the treatment of recurrent high-grade gliomas. Cancer 112:1139–1146

    Article  PubMed  CAS  Google Scholar 

  28. Wick W, Platten M, Weller M (2009) New (alternative) temozolomide regimens for the treatment of glioma. Neuro Oncol 11:69–79

    Article  PubMed  CAS  Google Scholar 

  29. Gasparini G (2001) Metronomic scheduling: the future of chemotherapy? Lancet Oncol 2:733–740

    Article  PubMed  CAS  Google Scholar 

  30. Kim JT, Kim JS, Ko KW et al (2006) Metronomic treatment of temozolomide inhibits tumor cell growth through reduction of angiogenesis and augmentation of apoptosis in orthotopic models of gliomas. Oncol Rep 16:33–39

    PubMed  Google Scholar 

  31. Kurzen H, Schmitt S, Naher H, Mohler T (2003) Inhibition of angiogenesis by non-toxic doses of temozolomide. Anticancer Drugs 14:515–522

    Article  PubMed  CAS  Google Scholar 

  32. Lee SM, Brada M, Stenning S, Thompson L, Gabe R (2008) A randomised trial of procarbazine, CCNU and vincristine (PCV) vs temozolomide (5-day or 21-day schedule) for recurrent high grade glioma (MRC BR12 ISRCTN83176944). Ann Oncol 19:viii2 (LBA 5)

    Article  Google Scholar 

  33. Rabik CA, Njoku MC, Dolan ME (2006) Inactivation of O6-alkylguanine DNA alkyltransferase as a means to enhance chemotherapy. Cancer Treat Rev 32:261–276

    Article  PubMed  CAS  Google Scholar 

  34. Turriziani M, Caporaso P, Bonmassar L et al (2006) O6-(4-bromothenyl)guanine (PaTrin-2), a novel inhibitor of O6-alkylguanine DNA alkyl-transferase, increases the inhibitory activity of temozolomide against human acute leukaemia cells in vitro. Pharmacol Res 53:317–323

    Article  PubMed  CAS  Google Scholar 

  35. Broniscer A, Gururangan S, MacDonald TJ et al (2007) Phase I trial of single-dose temozolomide and continuous administration of o6-benzylguanine in children with brain tumors: a pediatric brain tumor consortium report. Clin Cancer Res 13:6712–6718

    Article  PubMed  CAS  Google Scholar 

  36. Quinn JA, Desjardins A, Weingart J et al (2005) Phase I trial of temozolomide plus O6-benzylguanine for patients with recurrent or progressive malignant glioma. J Clin Oncol 23:7178–7187

    Article  PubMed  CAS  Google Scholar 

  37. Ranson M, Middleton MR, Bridgewater J et al (2006) Lomeguatrib, a potent inhibitor of O6-alkylguanine-DNA-alkyltransferase: phase I safety, pharmacodynamic, and pharmacokinetic trial and evaluation in combination with temozolomide in patients with advanced solid tumors. Clin Cancer Res 12:1577–1584

    Article  PubMed  CAS  Google Scholar 

  38. Khan OA, Ranson M, Michael M et al (2008) A phase II trial of lomeguatrib and temozolomide in metastatic colorectal cancer. Br J Cancer 98:1614–1618

    Article  PubMed  CAS  Google Scholar 

  39. Ranson M, Hersey P, Thompson D et al (2007) Randomized trial of the combination of lomeguatrib and temozolomide compared with temozolomide alone in chemotherapy naive patients with metastatic cutaneous melanoma. J Clin Oncol 25:2540–2545

    Article  PubMed  CAS  Google Scholar 

  40. Miknyoczki S, Chang H, Grobelny J et al (2007) The selective poly(ADP-ribose) polymerase-1(2) inhibitor, CEP-8983, increases the sensitivity of chemoresistant tumor cells to temozolomide and irinotecan but does not potentiate myelotoxicity. Mol Cancer Ther 6:2290–2302

    Article  PubMed  CAS  Google Scholar 

  41. Donawho CK, Luo Y, Luo Y et al (2007) ABT-888, an orally active poly(ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models. Clin Cancer Res 13:2728–2737

    Article  PubMed  CAS  Google Scholar 

  42. Ganiere V, Christen G, Bally F et al (2006) Listeria brain abscess, Pneumocystis pneumonia and Kaposi’s sarcoma after temozolomide. Nat Clin Pract Oncol 3:339–343 (quiz following 343)

    Article  PubMed  Google Scholar 

  43. FDA (2007) Temozolomide (marketed as Temodar): aplastic anemia. Drug Saf Newsl 1:7

    Google Scholar 

  44. Doyle TJ, Mikkelsen T, Croteau D et al (2005) Fatal hematologic toxicity with prolonged continuous administration of temozolomide (TMZ) during radiation therapy (RT) in the treatment of newly-diagnosed glioblastoma multiforme (GBM): report of a Phase II trial. J Clin Oncol 23 (abstract #1546)

  45. Jalali R, Singh P, Menon H, Gujral S (2007) Unexpected case of aplastic anemia in a patient with glioblastoma multiforme treated with Temozolomide. J Neurooncol 85:105–107

    Article  PubMed  Google Scholar 

  46. Morris B, Reiss U, Kasow K, Broniscer A (2008) Bone marrow transplantation (BMT) for aplastic anemia secondary to temozolomide therapy in a long-term survivor with glioblastomamultiforme (GBM). Neuro Oncol 10:396 (abstract CR2)

    Google Scholar 

  47. Singhal N, Selva-Nayagam S, Brown MP (2007) Prolonged and severe myelosuppression in two patients after low-dose temozolomide treatment—case study and review of literature. J Neurooncol 85:229–230

    Article  PubMed  CAS  Google Scholar 

  48. Villano JL, Collins CA, Manasanch EE et al (2006) Aplastic anaemia in patient with glioblastoma multiforme treated with temozolomide. Lancet Oncol 7:436–438

    Article  PubMed  Google Scholar 

  49. Gerber DE, Grossman SA, Zeltzman M et al (2007) The impact of thrombocytopenia from temozolomide and radiation in newly diagnosed adults with high-grade gliomas. Neuro Oncol 9:47–52

    Article  PubMed  CAS  Google Scholar 

  50. Noronha V, Berliner N, Ballen KK et al (2006) Treatment-related myelodysplasia/AML in a patient with a history of breast cancer and an oligodendroglioma treated with temozolomide: case study and review of the literature. Neuro Oncol 8:280–283

    Article  PubMed  Google Scholar 

  51. Su YW, Chang MC, Chiang MF, Hsieh RK (2005) Treatment-related myelodysplastic syndrome after temozolomide for recurrent high-grade glioma. J Neurooncol 71:315–318

    Article  PubMed  Google Scholar 

  52. Chamberlain MC, Glantz MJ, Chalmers L et al (2007) Early necrosis following concurrent Temodar and radiotherapy in patients with glioblastoma. J Neurooncol 82:81–83

    Article  PubMed  Google Scholar 

  53. Taal W, Brandsma D, de Bruin HG et al (2008) Incidence of early pseudo-progression in a cohort of malignant glioma patients treated with chemoirradiation with temozolomide. Cancer 113:405–410

    Article  PubMed  CAS  Google Scholar 

  54. Brandes AA, Franceschi E, Tosoni A et al (2008) MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients. J Clin Oncol 26:2192–2197

    Article  PubMed  Google Scholar 

  55. Ruben JD, Dally M, Bailey M et al (2006) Cerebral radiation necrosis: incidence, outcomes, and risk factors with emphasis on radiation parameters and chemotherapy. Int J Radiat Oncol Biol Phys 65:499–508

    PubMed  Google Scholar 

  56. Giglio P, Gilbert MR (2003) Cerebral radiation necrosis. Neurologist 9:180–188

    Article  PubMed  Google Scholar 

  57. Gerstner ER, McNamara MB, Norden AD et al (2009) Effect of adding temozolomide to radiation therapy on the incidence of pseudo-progression. J Neurooncol [Epub ahead of print]

  58. Macdonald DR, Cascino TL, Schold SC Jr, Cairncross JG (1990) Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 8:1277–1280

    PubMed  CAS  Google Scholar 

  59. Quan D, Hackney DB, Pruitt AA et al (1999) Transient MRI enhancement in a patient with seizures and previously resected glioma: use of MRS. Neurology 53:211–213

    PubMed  CAS  Google Scholar 

  60. Ananthnarayan S, Bahng J, Roring J et al (2008) Time course of imaging changes of GBM during extended bevacizumab treatment. J Neurooncol 88:339–347

    Article  PubMed  Google Scholar 

  61. Hau P, Koch D, Hundsberger T et al (2007) Safety and feasibility of long-term temozolomide treatment in patients with high-grade glioma. Neurology 68:688–690

    Article  PubMed  CAS  Google Scholar 

  62. Stupp R, Hottinger AF (2008) Management of malignant glioma—quo vadis? Onkologie 31:300–302

    Article  PubMed  Google Scholar 

Download references

Acknowledgments

We wish to thank Christa Williams for her design work.

Conflict of interest statement

None of the authors received any financial support based on the generation of this submission.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to J. Lee Villano.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Villano, J.L., Seery, T.E. & Bressler, L.R. Temozolomide in malignant gliomas: current use and future targets. Cancer Chemother Pharmacol 64, 647–655 (2009). https://doi.org/10.1007/s00280-009-1050-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00280-009-1050-5

Keywords

Navigation